Published on 8 Oct 2024 on GuruFocus.com · via Yahoo Finance
Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical...
Net Loss: Approximately $4.96 million for Q2 2024, or $0.46 per share.R&D Expenses: Approximately $3.9 million for Q2 2024, up from $3.6 million in Q2 2023.General and Administrative Expenses: Approximately $1.5 million for Q2 2024, down from $1.6 million in Q2 2023.Interest and Other Income: Approximately $449,000 for Q2 2024, compared to $444,000 in Q2 2023.Cash Position: Approximately $33.3 million as of June 30, 2024.Shares Outstanding: 10,758,805 shares of common stock as of June 30, 2024.Fully Diluted Shares Outstanding: Approximately 11.9 million shares as of June 30, 2024.
Warning! GuruFocus has detected 1 Warning Sign with LTRN.